

CD8 [C8/144B]

Concentrated and Prediluted Monoclonal Antibody
902-3160-070622

BIOCARE
M E D I C A L

Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
Q Series— For Leica BOND-III	ALR 3160 G7	7.0 mL	Ready-to-use	N/A

Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

Summary and Explanation:

The CD8 antibody reacts with the 32 kDa CD8 protein. CD8 stains cells with cytotoxic activity, including cortical thymocytes, cytotoxic/suppressor T-cells and a subset of natural killer cells. CD4 and CD8 positive and negative staining are indicative of T-cell neoplasms (1-2). CD4 and CD8 may also be used to differentiate between mycosis fungoides and cutaneous inflammatory processes (3-4). CD8 can be used in panels with CD4, CD56, TIA-1 to aid in identifying subsets of inflammatory skin diseases (5). Recently, CD8 has been used in panels with CD103, FOXP3, and PD-1 for the identification of CD8+ tumor infiltrating lymphocytes and their potential value for immune therapy (6-8).

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

Source: Mouse monoclonal

Species Reactivity: Human; others not tested

Clone: C8/144B

Isotype: IgG1/kappa

Protein Concentration: Call for lot specific Ig concentration.

Epitope/Antigen: CD8

Cellular Localization: Cell surface

Positive Tissue Control: Tonsil and normal colon

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Staining Protocol Recommendations (Q Series – For Leica BOND-III):

ALR3160 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

Protocol Name: IHC Protocol F

Detection: Bond Polymer Refine

HIER: 20 min with ER2

Peroxide Block: 5 min

Marker (Primary Antibody): 15 min

Post Primary: 8 min

Polymer: 8 min

Mixed DAB Refine: 10 min

Hematoxylin: 5 min

Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (9)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (10)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

Technical Support:

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.

References:

1. Barth TF, *et al.* Primary gastric apoptosis-rich T-cell lymphoma co-expressing CD4, CD8, and cytotoxic molecules. *Virchows Arch.* 2000 Apr; 436(4):357-64.

2. Williamson SL, *et al.* New monoclonal antibodies to the T cell antigens CD4 and CD8. Production and characterization in formalin-fixed paraffin-embedded tissue. *Am J Pathol.* 1998 Jun; 152(6):1421-6.

3. Deguchi M, *et al.* Proliferative activity of CD8(+) T cells as an important clue to analyze T cell-mediated inflammatory dermatoses. *Arch Dermatol Res.* 2001 Sep; 293 (9):442-7.

4. Izbán KF, *et al.* Immunohistochemical analysis of mycosis fungoides on paraffin-embedded tissue sections. *Mod Pathol.* 1998 Oct; 11(10):978-82.

5. Harvell JD, Nowfar-Rad M, Sundram U. An immunohistochemical study of CD4, CD8, TIA-1 and CD56 subsets in inflammatory skin disease. *J Cutan Pathol.* 2003 Feb;30(2):108-13.

6. Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. *Cancer Immunol Res.* 2015 Aug;3(8):926-35.

7. Liu S, *et al.* Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res.* 2014 Sep 6;16(5):432.

8. Tumeh PC, *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature.* 2014 Nov 27;515(7528):568-71.

9. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."

10. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.

 Biocare Medical

60 Berry Drive

Pacheco, CA 94553

USA

TP v1 (10/26/2021)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080